drugset / Trial / NCT07030699
A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The researchers are doing this study to find out whether the combination of epcoritamab with tafasitamab and lenalidomide is a safe and effective treatment for relapsed or refractory DLBCL. This is the first time the combination of drugs is being tested.
Timeline
- Start
- 2025-08-13
- Primary completion
- 2026-03-31
- Completion
- 2026-03-31
Outcome
Outcome not reported
Stopped (Enrollment): “Lack of accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epcoritamab | Monoclonal antibody | — | Subcutaneous |
| Subject | Lenalidomide | Other / unclassified | — | Oral |
| Subject | Tafasitamab | Monoclonal antibody | — | Intravenous |